Serina Therapeutics signs deal for up to USD 25 million unregistered common stock sales to Roth Principal Investments
Reuters2026/08/27 10:04- Serina Therapeutics signed a common stock purchase agreement with Roth Principal Investments for up to USD 25 million of newly issued common stock.
- Shares may be issued in unregistered sales under Securities Act Section 4(a)(2) and Rule 506(b), subject to conditions including an effective resale registration statement.
- Issuance cap set at 5,077,554 shares, or 19.99% of outstanding stock, unless shareholder approval is obtained or pricing meets a USD 2.77 base price.
- Roth ownership limited to 4.99% of outstanding shares; pricing set at a discount to VWAP, with no upper limit on price.
- Proceeds earmarked for working capital and general corporate purposes; agreement runs up to 36 months from commencement.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AirAsia says drug tests for all active pilots, cabin crew return negative results
GE HealthCare (GEHC.US) plans to acquire Sofie for $1 billion, aiming for high growth in the radiopharmaceutical sector
GE Healthcare plans to acquire Sofie for about $1 billion, aiming to expand recurring revenue by combining imaging devices with radiodiagnostic agents, in response to weak stock performance and pressure from activist investors.
Silver Price Forecast: XAG/USD bears have the upper hand below $64.75-$64.85 confluence
Resonac Holdings says RESONAC REPORT 2026 integrated report now available
Crypto prices
More
